Quest Launches New Hepatitis C Virus Test Capabilities for Recently FDA-approved Antiviral Therapies

Apr 14, 2016 MADISON, N.J., April 14, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has expanded its chronic hepatitis C virus (HCV) test services to include new capabilities to help physicians identify or predict resistance to several HCV therapies, including the recently FDA-approved Zepatierâ„¢, from Merck, and Daklinzaâ„¢, from Bristol-Myers Squibb. T...